Skip to main content
. Author manuscript; available in PMC: 2016 Jan 7.
Published in final edited form as: J Transl Sci. 2015 Jul 30;1(1):http://oatext.com/Molecular-analysis-of-CD133-positive-circulating-tumor-cells-from-patients-with-metastatic-castration-resistant-prostate-cancer.php.

Figure 2.

Figure 2

CD133 protein expression is prevalent in CTCs from patients with mCRPC. A. Representative dot plot comparing CD133neg and CD133pos CTCs from patients with mCRPC. B. Images of CD133neg and CD133pos cells from patients 9, 12, and 16. C. Percentages of CD133pos CTCs in individual patients with mCRPC. All twenty patients had detectable CD133pos CTCs, and on average 50.9% of their EpCAMpos CTCs were also positive for CD133. All images were captured on ImageStreamX. All cells included in the analyses were CD45-depleted, EpCAM-positive and had discernable nuclei when stained with FxCycle.